News

News

New Hope in High-Risk Leukemia Subtype

Philadelphia chromosome-like acute lymphocytic leukemia (Ph-like ALL) is a precursor of B-cell ALL. Unfortunately, pediatric patients with Ph-like ALL face worse outcomes. Adding tyrosine...
WIB_icon

MPL Expression Necessary for Development of Jak2V617F-Induced MPN

Results of a preclinical study showed that ablating the thrombopoietin (TPO) receptor (MPL) in Jak2V617F-positive mice prevented the development of myeloproliferative neoplasms (MPNs). The...
WIB_icon

Remission Duration Key to Survival in CLL After FCR

In spite of the efficacy of the treatment regimen of fludarabine, cyclophosphamide, and rituximab (FCR) in chronic lymphocytic leukemia (CLL), most CLL patients are...

The New Normal: Lower Transfusion Thresholds for Septic Shock Patients

A restrictive approach to blood transfusion reduced blood use by half but, more importantly, caused no harm to 998 critically ill patients with septic...

DS-ALL: An Ever-Changing Genetic Mutation Landscape

Children with Down syndrome are at an increased risk for developing leukemia – as much as 50 times more likely than other children. In...

ASH Brings Sickle Cell Disease Awareness to Capitol Hill

ASH Brings Sickle Cell Disease Awareness to Capitol Hill The National Heart, Lung, and Blood In-stitute’s (NHLBI) recently released expert panel report on the management...

Announcing This Year’s Top ASH Award Recipients

Each year, the Society recognizes outstanding hematologists who have made significant contributions to the field with the follow-ing awards: Wallace H. Coulter Award for...

A Possible Cheaper Test for Sickle Cell, Leukemia Drug May be Applicable to Other...

A Cheaper, Faster Test for Sickle Cell? Twelve minutes and 50 cents could be all it takes to diagnose sickle cell disease (SCD), if the...
WIB_icon

Once-Weekly Bortezomib Produced Durable Responses, Survival in Relapsed AL Amyloidosis

Results from a phase I/II study of single-agent bortezomib suggest that a once-weekly dosing regimen produced similar efficacy results to a twice-weekly regimen —...
WIB_icon

The Earlier the Better Early Response to Imatinib Predicted Outcomes in Children with CML

While imatinib has been proven effective for the majority of pediatric patients with chronic myeloid leukemia (CML), 13 to 25 percent of children still...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.